HTG Molecular Diagnostics Reports Full Year 2020 Results
HTG Molecular Diagnostics reported its financial results for the year ending December 31, 2020, highlighting a revenue decline to $8.5 million from $19.2 million in 2019, attributed primarily to the impacts of COVID-19. Product revenue fell to $7.9 million, linked to reduced clinical trial activities. Net loss from operations increased to $19.6 million, compared to $19.0 million the prior year. Despite challenges, HTG launched an Early Access Program for its new transcriptome panel and reported positive customer diversification trends, with nine new biopharma customers in 2020.
- Launched Early Access Program for new transcriptome panel with 15 participating organizations.
- Reported successful product development milestones amidst COVID-19 challenges.
- Diversified customer base, signing nine new biopharma customers in 2020.
- Total revenue decreased to $8.5 million from $19.2 million in 2019.
- Net loss from operations increased to $19.6 million, compared to $19.0 million last year.
- Collaborative development services revenue declined significantly to $0.7 million from $4.6 million.
Call scheduled for today, March 25, at 4:30pm ET
TUCSON, Ariz., March 25, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the year ended December 31, 2020.
Recent Business Highlights
In February 2021, released a second technical white paper characterizing HTG’s planned transcriptome panel using the HTG EdgeSeq technology (the “Panel”) that is in late-stage development. The white paper addresses the feasibility and performance of a prototype of the Panel for multiple cancer indications, as compared to RNA sequencing (“RNA-Seq”) including:
- Ability to differentiate samples based on gene expression profiles;
- Repeatability amongst replicates from multiple cancer indications with archived samples;
- Accuracy of differential expression analysis using a direct comparison to RNA-Seq; and
- Potential as a robust alternative to RNA-Seq for gene expression profiling while maintaining the advantages of the HTG EdgeSeq technology.
Launched an Early Access Program for the Panel in December 2020. Since this program was announced, 15 organizations have agreed to participate in this program. The Early Access Program is intended to allow select customers access to the panel in their laboratories or through services to be performed in HTG’s development laboratory prior to commercial launch of the Panel.
“Though it remains clear that COVID-19 placed significant pressure on our core oncology business, including planned studies and laboratory operations of our customers throughout 2020, we remained agile and continued to make strategic shifts in our business into areas less impacted by the pandemic throughout the year, and expect to continue to do so as we begin the next fiscal year,” said John Lubniewski, President and CEO of HTG. “We believe strategic adjustments made throughout 2020 to lessen the impact of COVID-19 on our business have been working. Our efforts to focus on customer diversification to include a larger number of smaller and mid-sized biopharma customers and academic medical centers, who have appeared to return to work more quickly than our larger customers, resulted in programs with a number of new customers, including 9 new biopharma customers in 2020. In addition, we worked diligently to adjust spending and commercial efforts to mitigate the impacts of COVID-19 on our organization throughout 2020, and believe our full year operating loss, ending cash and short-term available-for-sale investments balances reflect those efforts. The ultimate impact of COVID-19 remains uncertain, but we continue to see positive trends in non-oncology opportunities and believe direct revenue from our core oncology business will continue to move toward pre-COVID levels as vaccines are rolled out and global economies continue returning to work in 2021.”
Mr. Lubniewski continued, “Our product development team was able to perform on our key milestones throughout 2020 despite the challenges placed on our organization by COVID-19. We were very excited to share the details of our recent progress with the Panel in the white paper published in February and look forward to continued progress in the coming months as our development and marketing teams work toward design lock in the second quarter of 2021 and formal design verification and commercialization, currently scheduled for the third quarter of 2021. We look forward to the additional opportunities that this technology will present for HTG in the later part of 2021 and beyond.”
Full Year 2020 Financial Highlights:
Total revenue for the year ended December 31, 2020 was
Product and product-related services revenue was
Collaborative development services revenue for the year ended December 31, 2020 was
Net loss from operations for the year ended December 31, 2020 was
Cash, cash equivalents and short-term available-for-sale securities totaled
Conference Call and Webcast:
HTG will host a conference call for the investment community today beginning at 4:30 p.m. Eastern Time. Conference call and webcast details are as follows:
| Date: | Thursday, March 25, 2021 | |
| Time: | 4:30 p.m. Eastern Time | |
| Toll Free: | (877) 407-0789 | |
| International: | (201) 689-8562 | |
| Conference ID: | 13715845 | |
| Webcast: | http://public.viavid.com/index.php?id=143331 |
About HTG:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated performance characteristics and benefits of our planned transcriptome panel, the related Early Access Program, the impact of strategic adjustments made to lessen the impact of COVID-19, our belief that direct revenue from our core oncology business will begin to recover to pre-COVID levels, and the expected timing of the commercial launch of our transcriptome panel. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with the impact of the COVID-19 pandemic on us and our customers; the risk that our transcriptome panel may not provide the benefits that we expect; risks associated with our ability to develop and commercialize our products, including our transcriptome panel; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Annual Report on Form 10-K for the year ended December 31, 2020. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact:
Ashley Robinson
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
-Financial tables follow-
| HTG Molecular Diagnostics, Inc. | ||||||||
| Consolidated Statements of Operations | ||||||||
| Years Ended December 31, | ||||||||
| 2020 | 2019 | |||||||
| Revenue: | ||||||||
| Product and product-related services | $ | 7,890,854 | $ | 14,632,204 | ||||
| Collaborative development services | 658,010 | 4,571,684 | ||||||
| Total revenue | 8,548,864 | 19,203,888 | ||||||
| Operating expenses: | ||||||||
| Cost of product and product-related services revenue | 3,991,532 | 8,911,372 | ||||||
| Selling, general and administrative | 18,063,064 | 18,682,396 | ||||||
| Research and development | 6,079,907 | 10,570,225 | ||||||
| Total operating expenses | 28,134,503 | 38,163,993 | ||||||
| Operating loss | (19,585,639 | ) | (18,960,105 | ) | ||||
| Other income (expense), net | (747,770 | ) | (334,180 | ) | ||||
| Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note | (522,394 | ) | — | |||||
| Net loss before income taxes | (20,855,803 | ) | (19,294,285 | ) | ||||
| Provision for income taxes | (14,415 | ) | (3,379 | ) | ||||
| Net loss | $ | (20,870,218 | ) | $ | (19,297,664 | ) | ||
| Net loss per share, basic and diluted | $ | (4.51 | ) | $ | (7.60 | ) | ||
| Shares used in computing net loss per share, basic and diluted | 4,627,918 | 2,539,979 | ||||||
| HTG Molecular Diagnostics, Inc. | ||||||||
| Consolidated Balance Sheets | ||||||||
| December 31, | ||||||||
| 2020 | 2019 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 22,397,812 | $ | 7,619,748 | ||||
| Short-term investments available-for-sale, at fair value | 6,298,075 | 25,410,222 | ||||||
| Restricted cash | — | 3,270,247 | ||||||
| Accounts receivable | 1,588,767 | 3,164,176 | ||||||
| Inventory, net | 1,492,126 | 1,269,667 | ||||||
| Prepaid expenses and other | 1,094,273 | 633,522 | ||||||
| Total current assets | 32,871,053 | 41,367,582 | ||||||
| Operating lease right-of-use assets | 1,009,097 | 1,209,145 | ||||||
| Property and equipment, net | 1,227,402 | 2,240,133 | ||||||
| Other non-current assets | 90,356 | 302,409 | ||||||
| Total assets | $ | 35,197,908 | $ | 45,119,269 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,348,762 | $ | 1,662,583 | ||||
| Accrued liabilities | 1,459,878 | 1,870,296 | ||||||
| Contract liabilities - current | 185,083 | 426,014 | ||||||
| NuvoGen obligation - current | 512,729 | 1,152,233 | ||||||
| Current portion of long-term debt, net | 3,022,139 | 2,987,667 | ||||||
| Operating lease liabilities - current | 685,220 | 758,932 | ||||||
| Other current liabilities | 22,563 | 41,134 | ||||||
| Total current liabilities | 7,236,374 | 8,898,859 | ||||||
| NuvoGen obligation - non-current, net of discount | 4,479,396 | 4,498,777 | ||||||
| Long-term debt, net | 8,568,308 | 6,871,545 | ||||||
| Operating lease liabilities - non-current | 368,682 | 636,340 | ||||||
| Other non-current liabilities | 60,488 | 244,114 | ||||||
| Total liabilities | 20,713,248 | 21,149,635 | ||||||
| Commitments and Contingencies | ||||||||
| Total stockholders’ equity | 14,484,660 | 23,969,634 | ||||||
| Total liabilities and stockholders' equity | $ | 35,197,908 | $ | 45,119,269 | ||||
FAQ
What were HTG's total revenues for the year ended December 31, 2020?
How did COVID-19 impact HTG's financial performance in 2020?
What is HTG's net loss for the year ended December 31, 2020?
How many new biopharma customers did HTG acquire in 2020?
When will HTG officially launch its new transcriptome panel?
